Corvus Pharma director files initial Form 3

Q: What does Andrew C. Chan’s Form 3 filing for CRVS show?

The Form 3 filing shows that Andrew C. Chan is a director of Corvus Pharmaceuticals, Inc. It is an initial statement of beneficial ownership and indicates no reportable insider transactions, purchases, or sales in CRVS at the time of this filing.

Q: Does the CRVS Form 3 for Andrew C. Chan report any stock purchases or sales?

No. The transaction summary in Andrew C. Chan’s Form 3 for Corvus Pharmaceuticals shows zero buys, zero sells, and no derivative exercises. It is purely an initial ownership report without recorded trading activity in CRVS shares.

Q: What role does Andrew C. Chan have at Corvus Pharmaceuticals (CRVS)?

The Form 3 identifies Andrew C. Chan as a director of Corvus Pharmaceuticals, Inc. Directors are considered insiders under SEC rules and must report their beneficial ownership and subsequent transactions in CRVS securities through Forms 3, 4, and 5.

Q: Why is a Form 3 important for Corvus Pharmaceuticals investors?

Form 3 provides an insider’s initial beneficial ownership position when they become a reporting person. For Corvus Pharmaceuticals (CRVS), Andrew C. Chan’s Form 3 establishes his status as a director and a baseline for any future reportable transactions in the company’s securities.

Corvus Pharmaceuticals, Inc. director Andrew C. Chan filed a Form 3, which is an initial statement of beneficial ownership for insiders.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Corvus Pharmaceuticals, Inc. director Andrew C. Chan filed a Form 3, which is an initial statement of beneficial ownership for insiders. The filing lists him as a director and shows no reportable insider transactions, purchases, or sales at this time.

Key Figures

Buy transactions: 0 transactions Sell transactions: 0 transactions Derivative transactions: 0 transactions +1 more

4 metrics

Buy transactions 0 transactions Form 3 transaction summary for Andrew C. Chan

Sell transactions 0 transactions Form 3 transaction summary for Andrew C. Chan

Derivative transactions 0 transactions Form 3 derivative transaction count

Net buy/sell direction neutral Form 3 netBuySellDirection indicator

Key Terms

Form 3, reportingPersons, transactionSummary, derivativeSummary

4 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3):"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reportingPersons regulatory

""reportingPersons": [ { "name": "Chan Andrew C.","

transactionSummary financial

""transactionSummary": { "buyCount": 0, "sellCount": 0,"

derivativeSummary financial

""derivativeSummary": [],"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Andrew C. Chan’s Form 3 filing for CRVS show?

The Form 3 filing shows that Andrew C. Chan is a director of Corvus Pharmaceuticals, Inc. It is an initial statement of beneficial ownership and indicates no reportable insider transactions, purchases, or sales in CRVS at the time of this filing.

Does the CRVS Form 3 for Andrew C. Chan report any stock purchases or sales?

No. The transaction summary in Andrew C. Chan’s Form 3 for Corvus Pharmaceuticals shows zero buys, zero sells, and no derivative exercises. It is purely an initial ownership report without recorded trading activity in CRVS shares.

What role does Andrew C. Chan have at Corvus Pharmaceuticals (CRVS)?

The Form 3 identifies Andrew C. Chan as a director of Corvus Pharmaceuticals, Inc. Directors are considered insiders under SEC rules and must report their beneficial ownership and subsequent transactions in CRVS securities through Forms 3, 4, and 5.

Why is a Form 3 important for Corvus Pharmaceuticals investors?

Form 3 provides an insider’s initial beneficial ownership position when they become a reporting person. For Corvus Pharmaceuticals (CRVS), Andrew C. Chan’s Form 3 establishes his status as a director and a baseline for any future reportable transactions in the company’s securities.

Are there any derivative securities reported in Andrew C. Chan’s CRVS Form 3?

No derivative securities are reported. The filing’s derivative summary is empty and transaction counts, including derivative transactions, are zero. This means Andrew C. Chan’s Form 3 for CRVS does not list options, warrants, or other derivative positions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/27/2026 - 05:31 PM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Chan Andrew C.

(Last)

(First)

(Middle)

C/O CORVUS PHARMACEUTICALS, INC.

901 GATEWAY BOULEVARD, THIRD FLOOR

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/23/2026

3. Issuer Name and Ticker or Trading Symbol
Corvus Pharmaceuticals, Inc. [ CRVS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:

Remarks:

Exhibit 24.1 - Power of Attorney

No securities are beneficially owned.

	/s/ Leiv Lea, as Attorney-in-Fact for Andrew C. Chan	04/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR